BioSpace News Archive

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present preclinical data supporting its lead clinical oncology program, RTX-240, at the upcoming Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting. The meeting is being held virtually from Novem

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Premal Patel, M.D., Ph.D., as chief medical officer.

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of October 2020, which is payable on November 16, 2020 to shareholders of record at the close of business on October 30, 2020.

-- mRNA-based vaccine candidate MRT5500 induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies -- -- Two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients -- -- Phase 1/2 clinical trial anticipated to begin in the fourth quarter of 2020 --

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutchison AO, MD – the company’s CEO and president– was named the recipient of the Advance 2020 Global Impact award. The Advance awards recognize the work of remarkable global Australians making an extraordinary

AGC Biologics, a leading global biopharmaceutical contract development and manufacturing organization (CDMO), has announced a leadership update at the United States and Copenhagen facilities

- Poster presentation highlights data from the U.S. phase 1 trial of lemzoparlimab, a highly differentiated anti-CD47 monoclonal antibody, for treatment of relapsed or refractory malignancy

Blue Cross Blue Shield of Massachusetts has been named a “Best Company for Dads” by Working Mother in a recognition of the company’s supportive policies. The award celebrates organizations that lead in the areas of parental leave, chi

ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2020 financial results. ViewRay will hold a conference call to discuss results on Thursday, November 5,

Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that it has sold $25 million of unsecured convertible promissory notes to funds affiliated with Adjuvant Capital, LP (“Adjuvant Capital”). The notes are convertible into shares of Evofem common stock at a conversion price of $3.65 per share. Proceeds from the sale of the notes